Abstract
Background: Alefacept has been recently approved for the treatment of chronic plaque psoriasis vulgaris. Its use for the treatment of nail disease has not been documented. Alefacept is believed to be active in psoriasis by affecting the interaction between LFA-3 on an antigen presenting cell and CD2 on activated T-cells. In addition, alefacept binds to activated CD4+CD45RO+ cells and through interaction with NK cells causes T-cell apoptosis. Affects on nail disease have not been presented in the formal studies of this drug. This poster presents my observation of a single patient with severe psoriatic nail involvement whose nails improved in conjunction with improvement of his overall disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
